B-Cell Lymphomas – Pipeline Review, H1 2012

B-Cell Lymphomas – Pipeline Review, H1 2012


January 23, 2012
326 Pages - SKU: GMD6775865
License type:
Online Download      US $500.00
Global Site License      US $1,500.00
B-Cell Lymphomas - Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'B-Cell Lymphomas - Pipeline Review, H1 2012', provides an overview of the B-Cell Lymphomas therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Lymphomas. 'B-Cell Lymphomas - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for B-Cell Lymphomas.
  • A review of the B-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the B-Cell Lymphomas pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for B-Cell Lymphomas.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding B-Cell Lymphomas pipeline depth and focus of B-Cell Lymphomas therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.



More Oncology/Hematology reports by Global Markets Direct

Colon Carcinoma - Pipeline Review, H1 2014 by Global Markets Direct
Colon Carcinoma - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Colon Carcinoma - Pipeline Review, H1 2014’, provides an overview of the Colon Carcinoma’s therapeutic pipeline.This ...
Endometrial Cancer - Pipeline Review, H1 2014 by Global Markets Direct
Endometrial Cancer - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Endometrial Cancer - Pipeline Review, H1 2014’, provides an overview of the Endometrial Cancer’s therapeutic pipeline.This ...
Metastatic Liver Cancer - Pipeline Review, H1 2014 by Global Markets Direct
Metastatic Liver Cancer - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Metastatic Liver Cancer - Pipeline Review, H1 2014’, provides an overview of the Metastatic Liver ...
Medullary Thyroid Cancer - Pipeline Review, H1 2014 by Global Markets Direct
Medullary Thyroid Cancer - Pipeline Review, H1 2014SummaryGlobal Markets Direct’s, ‘Medullary Thyroid Cancer - Pipeline Review, H1 2014’, provides an overview of the Medullary Thyroid ...
See all reports like this >>